These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1719686)

  • 21. Cross-comparison of PSA and PAP values in a wide spectrum of prostate cancer conditions.
    Tarle M
    Anticancer Res; 1988; 8(4):569-72. PubMed ID: 2460018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The role of PSA in prostatic adenocarcinoma].
    Manca GP
    Minerva Med; 1990 Apr; 81(4):261-4. PubMed ID: 1692981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-specific antigen: a valuable clinical tool.
    Oesterling JE
    Oncology (Williston Park); 1991 Apr; 5(4):107-22; discussion 122, 125-6, 128. PubMed ID: 1714288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is prostate-specific antigen still the best tumor marker for prostate cancer?
    Leewansangtong S; Soontrapa S; Tantiwong A
    J Med Assoc Thai; 1999 Oct; 82(10):1034-40. PubMed ID: 10561969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer.
    Ricciardelli C; Mayne K; Sykes PJ; Raymond WA; McCaul K; Marshall VR; Horsfall DJ
    Clin Cancer Res; 1998 Apr; 4(4):963-71. PubMed ID: 9563891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [PSA in the staging and monitoring of cancer of the prostate].
    Gil Sanz MJ; Sanz Velez JI; Liedana Torres JM; Roncales Badal AL; Allepuz Losa C; Rioja Sanz LA
    Actas Urol Esp; 1991; 15(6):527-31. PubMed ID: 1724347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer].
    Akimoto S; Akakura K; Shimazaki J
    Hinyokika Kiyo; 1988 Aug; 34(8):1389-96. PubMed ID: 2461644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate specific antigen as tumor marker: relationship with histologic grading.
    Xess A; Singh M; Raghwendra KH; Sharma HP; Shahi SK
    Indian J Pathol Microbiol; 2001 Jul; 44(3):261-4. PubMed ID: 12024909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prognosis in stage a prostate cancer].
    Murase T; Kuriyama M; Maeda S; Ando Y; Itoh H; Watanabe H
    Hinyokika Kiyo; 1996 Sep; 42(9):639-43. PubMed ID: 8918661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical study of stage a prostatic cancer detected incidentally by transurethral resection of the prostate].
    Nakanishi S; Gotou T; Sawada A; Shibasaki N; Ishitoya T; Okumura K
    Hinyokika Kiyo; 2009 Jan; 55(1):5-8. PubMed ID: 19227204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical study of prostate specific antigen failure after radical prostatectomy for prostate cancer: a single center experience].
    Taue R; Takahashi M; Fukawa T; Koizumi T; Nakanishi R; Yamaguchi K; Yamamoto Y; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Fukumori T; Kanayama HO
    Hinyokika Kiyo; 2009 Jan; 55(1):1-4. PubMed ID: 19227203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Advanced prostate cancer with normal serum prostate-specific antigen values].
    Komura T; Yamagiwa K; Ogura H; Kohjimoto Y; Ohkawa T; Inagaki T; Ebisuno S; Senzaki A
    Hinyokika Kiyo; 1998 May; 44(5):303-6. PubMed ID: 9656099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
    Morote J; Lorente JA; Encabo G
    Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical profiles of prostate cancer in our hospital: association between primary symptoms and clinical stage].
    Kimura T; Ikemoto I; Ohishi Y
    Hinyokika Kiyo; 2000 Feb; 46(2):83-6. PubMed ID: 10769794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
    Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer].
    de La Taille A; Houlgatte A; Houdelette P; Berlizot P; Fournier R; Ricordel I
    Prog Urol; 1997 Jun; 7(3):455-63. PubMed ID: 9273075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.